These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 36619226)

  • 21. Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review.
    Alfaraidi H; Samaan MC
    Front Endocrinol (Lausanne); 2022; 13():1072879. PubMed ID: 36814831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.
    Rajpathak SN; Rajgopalan S; Engel SS
    J Diabetes Complications; 2014; 28(6):831-5. PubMed ID: 25104238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?
    Emami-Riedmaier A; Schaeffeler E; Nies AT; Mörike K; Schwab M
    J Intern Med; 2015 Feb; 277(2):235-247. PubMed ID: 25418285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin: Is it a drug for all reasons and diseases?
    Triggle CR; Mohammed I; Bshesh K; Marei I; Ye K; Ding H; MacDonald R; Hollenberg MD; Hill MA
    Metabolism; 2022 Aug; 133():155223. PubMed ID: 35640743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?
    Florez JC
    Diabetologia; 2017 May; 60(5):800-807. PubMed ID: 28283684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics and personalized treatment of type 2 diabetes.
    Semiz S; Dujic T; Causevic A
    Biochem Med (Zagreb); 2013; 23(2):154-71. PubMed ID: 23894862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetics of oral antidiabetic treatment.
    Schroner Z; Javorsky M; Kozarova M; Tkac I
    Bratisl Lek Listy; 2011; 112(8):441-6. PubMed ID: 21863614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
    Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
    J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review.
    Mofo Mato EP; Guewo-Fokeng M; Essop MF; Owira PMO
    Medicine (Baltimore); 2018 Jul; 97(27):e11349. PubMed ID: 29979413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
    Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
    Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gut microbiome encoded purine and amino acid pathways present prospective biomarkers for predicting metformin therapy efficacy in newly diagnosed T2D patients.
    Elbere I; Orlovskis Z; Ansone L; Silamikelis I; Jagare L; Birzniece L; Megnis K; Leskovskis K; Vaska A; Turks M; Klavins K; Pirags V; Briviba M; Klovins J
    Gut Microbes; 2024; 16(1):2361491. PubMed ID: 38868903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine.
    Mannino GC; Andreozzi F; Sesti G
    Diabetes Metab Res Rev; 2019 Mar; 35(3):e3109. PubMed ID: 30515958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes.
    Xu T; Brandmaier S; Messias AC; Herder C; Draisma HH; Demirkan A; Yu Z; Ried JS; Haller T; Heier M; Campillos M; Fobo G; Stark R; Holzapfel C; Adam J; Chi S; Rotter M; Panni T; Quante AS; He Y; Prehn C; Roemisch-Margl W; Kastenmüller G; Willemsen G; Pool R; Kasa K; van Dijk KW; Hankemeier T; Meisinger C; Thorand B; Ruepp A; Hrabé de Angelis M; Li Y; Wichmann HE; Stratmann B; Strauch K; Metspalu A; Gieger C; Suhre K; Adamski J; Illig T; Rathmann W; Roden M; Peters A; van Duijn CM; Boomsma DI; Meitinger T; Wang-Sattler R
    Diabetes Care; 2015 Oct; 38(10):1858-67. PubMed ID: 26251408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics of metformin response: a step in the path toward personalized medicine.
    Reitman ML; Schadt EE
    J Clin Invest; 2007 May; 117(5):1226-9. PubMed ID: 17476355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current understanding of the pharmacogenomics of metformin.
    Zolk O
    Clin Pharmacol Ther; 2009 Dec; 86(6):595-8. PubMed ID: 19915604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic and Phenotypic Factors Affecting Glycemic Response to Metformin Therapy in Patients with Type 2 Diabetes Mellitus.
    Nasykhova YA; Barbitoff YA; Tonyan ZN; Danilova MM; Nevzorov IA; Komandresova TM; Mikhailova AA; Vasilieva TV; Glavnova OB; Yarmolinskaya MI; Sluchanko EI; Glotov AS
    Genes (Basel); 2022 Jul; 13(8):. PubMed ID: 35893047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial.
    Ji L; Li H; Guo X; Li Y; Hu R; Zhu Z
    PLoS One; 2013; 8(2):e57222. PubMed ID: 23468941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients.
    Xiao D; Zhang SM; Li X; Yin JY; Gong WJ; Zheng Y; Xu XJ; Lin X; Ji LN; Liu RR; Tang Q; Zhang W; Zhou HH; Han XY; Liu ZQ
    Pharmacogenomics; 2015; 16(14):1621-9. PubMed ID: 26401715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single nucleotide polymorphisms in the intergenic region between metformin transporter OCT2 and OCT3 coding genes are associated with short-term response to metformin monotherapy in type 2 diabetes mellitus patients.
    Zaharenko L; Kalnina I; Geldnere K; Konrade I; Grinberga S; Židzik J; Javorský M; Lejnieks A; Nikitina-Zake L; Fridmanis D; Peculis R; Radovica-Spalvina I; Hartmane D; Pugovics O; Tkáč I; Klimčáková L; Pīrāgs V; Klovins J
    Eur J Endocrinol; 2016 Dec; 175(6):531-540. PubMed ID: 27609360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management.
    Kyriakidou A; Koufakis T; Goulis DG; Vasilopoulos Y; Zebekakis P; Kotsa K
    Curr Pharm Des; 2021; 27(8):1025-1034. PubMed ID: 33272167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.